Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroendocrine Tumor Development and Cardiovascular Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHGA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHGA Recombinant Protein (Full-length & Cleaved Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CHGA Products |
| Gene Delivery | CHGA Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View CHGA Products |
| Benchmark Ab | Anti-CHGA Recombinant Antibody Recombinant positive control for ELISA, IHC, and Western Blot validation. |
View CHGA Products |
| Validator | CHGA siRNA Set For knockdown verification in neuroendocrine cell models. |
View CHGA Products |
| Related Target A | SSTR2 (Somatostatin Receptor 2) Co-expressed biomarker in neuroendocrine tumors; primary target for peptide receptor radionuclide therapy (PRRT). |
View SSTR2 Products |
| Related Target B | SYP (Synaptophysin) Complementary neuroendocrine marker used in panel assays for cancer differentiation. |
View SYP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High susceptibility to proteolytic cleavage in vitro | Sequence-verified, stable recombinant fragments (e.g., Vasostatin, Catestatin domains) with precise boundary definitions. |
| Post-translational modification (PTM) dependency | HEK293 mammalian expression host ensures native-like O-glycosylation and phosphorylation patterns. |
| Lack of consistent reference standards | Sequence-derived recombinant benchmark antibodies ensure batch-to-batch reproducibility. |
| Non-specific binding in complex matrices | High purity (>95% by SDS-PAGE) reduces background noise in serum-based ELISA development. |
Live CHGA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical utility of Chromogranin A (CHGA) is expanding beyond its established role as the gold-standard diagnostic serum biomarker for neuroendocrine tumors (NETs). Current drug discovery pipelines are increasingly targeting CHGA and its cleavage peptides (such as Catestatin and Vasostatin) for therapeutic intervention in cardiovascular diseases, metabolic disorders, and advanced prostate cancer exhibiting neuroendocrine differentiation.
As therapeutic strategies transition from diagnostic monitoring to targeted monoclonal antibodies and peptide-based therapeutics, the demand for highly defined, structurally intact recombinant proteins and specific cleavage-product antigens has intensified. Developers are focusing on differentiating full-length CHGA from its biologically active fragments to mitigate off-target cardiovascular effects and optimize diagnostic sensitivity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Diagnostics) | Roche (Ventana), Abbott, Siemens Healthineers | Neuroendocrine Tumors (NETs), Small Cell Lung Cancer (SCLC) | High-Purity HEK293-expressed CHGA Antigen for antibody screening and clinical assay calibration. |
| Peptide Therapeutics (Catestatin-derived) | Academic Medical Centers, Biotech Startups | Hypertension, Inflammatory Bowel Disease (IBD) | Truncated CHGA domain proteins with verified sequences and precise molecular weight control. |
| Companion Diagnostics (IHC Panels) | Dako (Agilent), Leica Biosystems | Prostate Cancer (NE Differentiation) | Recombinant Benchmark Antibodies to establish highly reproducible positive controls. |